A prospective, observational trial to further assess safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mcrc) in routine clinical practice (correlate)

Abstract

Background: The oral multikinase inhibitor regorafenib significantly improved overall survival vs placebo (HR 0.77, p = 0.0052) in patients with mCRC that progressed on available treatments in the randomized, double-blind, placebo-controlled CORRECT trial (Grothey, Van Cutsem et al. Lancet 2013). CORRELATE will characterize the safety and efficacy of regorafenib in real-world clinical practice. Trial design: This prospective, observational, multicenter trial (ClinicalTrials.gov identifier NCT02042144) will be conducted in routine clinical practice settings in more than 25 countries in Europe, Latin America, and the Asia-Pacific region. The trial will recruit 3,000 patients with mCRC previously treated with other approved therapies and for whom a decision has been made to treat with regorafenib. Patients will receive oral regorafenib 160 mg once daily for weeks 1–3 of each 4-week cycle. Dose interruptions and reductions will be permitted for the management of adverse events. The primary endpoint is the incidence of treatment-emergent adverse events, assessed using National Cancer Institute Common Terminology Criteria for Adverse Events. Secondary endpoints are overall survival, progression-free survival, disease control rate, health-related quality of life (assessed using the EQ-5D questionnaire), and healthcare resource use. Data sources will include medical records, routine measurements, and patient-reported outcome questionnaires. All patients receiving ≥1 dose of regorafenib will be included in the overall analysis. Two planned interim assessments will occur after 1,000 and 2,000 patients have been observed for ≥3 months. The final analysis will be performed when all patients have been followed for ≥18 months from the time they discontinue regorafenib (unless they withdrew from the trial early because of death, consent withdrawal, or patient/investigator decision to stop). Recruitment is under way, with the first patient enrolled in April 2014; the estimated primary completion date is July 2017. Disclosure: M.P. Ducreux: has the following financial disclosures: Advisory board: Merck, Roche, Bohringer, Amgen, Novartis, Sanofi Corporate sponsored research: Roche, Pfizer Employment (wife): Sandoz; A. Falcone: Advisory Boards for Amgen, Bayer, Roche, Merck Serono, Sanofi and Corporate Sponsored Research for Amgen, Bayer, Roche, Merck Serono, Sanofi; C.J.A. Punt: has the following financial disclosures: Advisory board: Roche, Amgen, Sanofi, Nordic Pharma, Bayer; J. Thaler: has the following financial disclosures: Advisory board: Bayer, Merck. All other authors have declared no conflicts of interest.